Cargando…
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence
BACKGROUND: Flexible dosing of anticholinergics used for overactive bladder (OAB) treatment is a useful strategy in clinical practice for achieving a maximum effective and maximum tolerated level of therapeutic benefit. In this post hoc analysis we evaluated the efficacy and tolerability of trospium...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945343/ https://www.ncbi.nlm.nih.gov/pubmed/20840754 http://dx.doi.org/10.1186/1471-2490-10-15 |
_version_ | 1782187211669635072 |
---|---|
author | Bödeker, Rolf-Hasso Madersbacher, Helmut Neumeister, Claudia Zellner, Michael |
author_facet | Bödeker, Rolf-Hasso Madersbacher, Helmut Neumeister, Claudia Zellner, Michael |
author_sort | Bödeker, Rolf-Hasso |
collection | PubMed |
description | BACKGROUND: Flexible dosing of anticholinergics used for overactive bladder (OAB) treatment is a useful strategy in clinical practice for achieving a maximum effective and maximum tolerated level of therapeutic benefit. In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing. METHODS: The data came from a 12-week, randomised, double-blind, phase IIIb study in which 1658 patients with urinary frequency plus urge incontinence received trospium chloride 15 mg TID (n = 828) or 2.5 mg oxybutynin hydrochloride TID (n = 830). After four weeks, daily doses were doubled and not readjusted in 29.2% (242/828) of patients in the trospium group, and in 23.3% (193/830) in the oxybuytnin group, until the end of treatment. We assessed the absolute reduction in weekly UUI episodes and the change in intensity of dry mouth, recorded in patients' micturition diaries. Adverse events were also evaluated. Statistics were descriptive. RESULTS: Dose escalation of either trospium or oxybutynin increased reduction in UUI episodes in the population studied. At study end, there were no relevant differences between the "dose adjustment" subgroups and the respective "no dose adjustment" subgroups (trospium: P = 0.249; oxybutynin: P = 0.349). After dose escalation, worsening of dry mouth was higher in both dose adjusted subgroups compared to the respective "no dose adjustment" subgroups (P < 0.001). Worsening of dry mouth was lower in the trospium groups than in the oxybutynin groups (P < 0.001). Adverse events were increased in the dose adjusted subgroups. CONCLUSIONS: Flexible dosing of trospium was proven to be as effective, but better tolerated as the officially approved adjusted dose of oxybutynin. TRIAL REGISTRATION (PARENT STUDY): The study was registered with the German Federal Institute for Drugs and Medical Devices (BfArM, Berlin, Germany), registration number 4022383, as required at the time point of planning this study. |
format | Text |
id | pubmed-2945343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29453432010-09-26 Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence Bödeker, Rolf-Hasso Madersbacher, Helmut Neumeister, Claudia Zellner, Michael BMC Urol Research Article BACKGROUND: Flexible dosing of anticholinergics used for overactive bladder (OAB) treatment is a useful strategy in clinical practice for achieving a maximum effective and maximum tolerated level of therapeutic benefit. In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing. METHODS: The data came from a 12-week, randomised, double-blind, phase IIIb study in which 1658 patients with urinary frequency plus urge incontinence received trospium chloride 15 mg TID (n = 828) or 2.5 mg oxybutynin hydrochloride TID (n = 830). After four weeks, daily doses were doubled and not readjusted in 29.2% (242/828) of patients in the trospium group, and in 23.3% (193/830) in the oxybuytnin group, until the end of treatment. We assessed the absolute reduction in weekly UUI episodes and the change in intensity of dry mouth, recorded in patients' micturition diaries. Adverse events were also evaluated. Statistics were descriptive. RESULTS: Dose escalation of either trospium or oxybutynin increased reduction in UUI episodes in the population studied. At study end, there were no relevant differences between the "dose adjustment" subgroups and the respective "no dose adjustment" subgroups (trospium: P = 0.249; oxybutynin: P = 0.349). After dose escalation, worsening of dry mouth was higher in both dose adjusted subgroups compared to the respective "no dose adjustment" subgroups (P < 0.001). Worsening of dry mouth was lower in the trospium groups than in the oxybutynin groups (P < 0.001). Adverse events were increased in the dose adjusted subgroups. CONCLUSIONS: Flexible dosing of trospium was proven to be as effective, but better tolerated as the officially approved adjusted dose of oxybutynin. TRIAL REGISTRATION (PARENT STUDY): The study was registered with the German Federal Institute for Drugs and Medical Devices (BfArM, Berlin, Germany), registration number 4022383, as required at the time point of planning this study. BioMed Central 2010-09-14 /pmc/articles/PMC2945343/ /pubmed/20840754 http://dx.doi.org/10.1186/1471-2490-10-15 Text en Copyright ©2010 Bödeker et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bödeker, Rolf-Hasso Madersbacher, Helmut Neumeister, Claudia Zellner, Michael Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title_full | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title_fullStr | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title_full_unstemmed | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title_short | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
title_sort | dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945343/ https://www.ncbi.nlm.nih.gov/pubmed/20840754 http://dx.doi.org/10.1186/1471-2490-10-15 |
work_keys_str_mv | AT bodekerrolfhasso doseescalationimprovestherapeuticoutcomeposthocanalysisofdatafroma12weekmulticentredoubleblindparallelgrouptrialoftrospiumchlorideinpatientswithurinaryurgeincontinence AT madersbacherhelmut doseescalationimprovestherapeuticoutcomeposthocanalysisofdatafroma12weekmulticentredoubleblindparallelgrouptrialoftrospiumchlorideinpatientswithurinaryurgeincontinence AT neumeisterclaudia doseescalationimprovestherapeuticoutcomeposthocanalysisofdatafroma12weekmulticentredoubleblindparallelgrouptrialoftrospiumchlorideinpatientswithurinaryurgeincontinence AT zellnermichael doseescalationimprovestherapeuticoutcomeposthocanalysisofdatafroma12weekmulticentredoubleblindparallelgrouptrialoftrospiumchlorideinpatientswithurinaryurgeincontinence |